Literature DB >> 8823380

An Epstein Barr virus-related cross reactive autoimmune response in multiple sclerosis in Norway.

J H Vaughan1, T Riise, G H Rhodes, M D Nguyen, E Barrett-Connor, H Nyland.   

Abstract

In studies of patients in Norway with multiple sclerosis (MS), we have found cross reactive autoantibodies related to the Epstein Barr virus nuclear antigen-1 (EBNA-1). The MS patients had elevated IgG antibody to EBNA-1, as measured by reactivity with a synthetic glycine/alanine peptide, P62, which represents the glycine/alanine repeat in EBNA-1. The mean titer of anti-P62 in patients with acute relapse at the time of assay was significantly higher than in the remaining patients. Patients with remitting/relapsing MS also had elevated autoantibody to a lymphocyte protein, p542, cross reactive with EBNA-1 through a glycine/serine epitope. High titered anti-EBNA-1 antibodies from some MS, as well as from some SLE sera, were shown to cross react with 80-82 kDa and 60 kDa proteins in neuroglial cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8823380     DOI: 10.1016/0165-5728(96)00069-0

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  4 in total

Review 1.  Epstein-barr virus infection and multiple sclerosis: a review.

Authors:  Alberto Ascherio; Kassandra L Munger
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-06       Impact factor: 4.147

2.  Antibodies specific for Epstein-Barr virus nuclear antigen-1 cross-react with human heterogeneous nuclear ribonucleoprotein L.

Authors:  J William Lindsey; Samantha L deGannes; Kimberly A Pate; Xiurong Zhao
Journal:  Mol Immunol       Date:  2015-11-28       Impact factor: 4.407

3.  Serum uric acid and risk of multiple sclerosis.

Authors:  Jennifer Massa; E O'Reilly; K L Munger; G N Delorenze; A Ascherio
Journal:  J Neurol       Date:  2009-05-26       Impact factor: 4.849

Review 4.  The Role of Latently Infected B Cells in CNS Autoimmunity.

Authors:  Ana Citlali Márquez; Marc Steven Horwitz
Journal:  Front Immunol       Date:  2015-10-28       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.